- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Hematology/Oncology :: Hematology/Oncology Conferences
30th Annual SABCS
December 12-16, 2007 San Antonio, Texas- Completion axillary dissection may not be required after positive sentinel node biopsy
- Denosumab increases BMD in women with breast cancer receiving AI therapy, findings indicate
- Continuation of tamoxifen beyond standard 5 years reduces breast cancer recurrence, preliminary data show
- Anastrozole appears superior to tamoxifen in reducing risk of recurrence in patients with early breast cancer, data show
- Docetaxel plus cyclophosphamide improves overall survival better than standard chemotherapy in women with breast cancer, data show
- AstraZeneca to stop development of olaparib for ovarian cancer
- Baxter's Advate approved as only factor VIII for routine prophylaxis in adults, children with hemophilia A
- FDA approves Insys' sublingual fentanyl spray to treat breakthrough cancer pain
- FDA grants orphan drug designation to Amsterdam Molecular Therapeutics' gene therapy for hemophilia B
- CanBas' CBP501 granted orphan drug status as treatment for malignant mesothelioma
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA approves new label for Novartis' Gleevec recommending longer treatment duration for Kit-positive GIST, grants Gleevec regular approval in this indication
- AstraZeneca signs separate agreements with Prosidion, Hutchison Medi Pharma
- ArQule's tivantinib reaches main goal in midstage trial of patients with liver cancer
- Kinex acquires U.S., European rights to cancer technology, products from Hanmi
